Sun Pharmaceutical (SUNPHARMA) — Financial Results

Sun Pharmaceutical Industries Limited announced unaudited Q3 FY26 financial results for the quarter and nine months ended December 31, 2025, filed on February 1, 2026. The company faces a customs duty contingent liability of ₹1,819.66 lakhs pending Supreme Court review and recorded an incremental labor code compliance liability of ₹226.33 lakhs. A subsidiary undergoing operational shutdown has assets classified as held for sale valued at ₹530.18 lakhs. Results were approved by the board on January 30, 2026.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SUNPHARMA ✨ Ask AI About This

About Sun Pharmaceutical Industries Limited (SUNPHARMA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹4,50,643.09 Cr P/E: 41.3 ROE: 15.1% ROCE: 20.3%

View full SUNPHARMA stock details →

📡 Get AI alerts when SUNPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SUNPHARMA — Free

💡 Ask AI about this filing

"How does this financial results affect Sun Pharmaceutical Industries Limited's outlook?" "What did Sun Pharmaceutical Industries Limited announce on 1 February 2026?" "Is this positive or negative for SUNPHARMA?"

Ask AI Free →

📊 More SUNPHARMA filings

See all SUNPHARMA filings →

🔥 Also filed on 1 February 2026

TRENT Trent Limited Announcement DELHIVERY Delhivery Limited Financial Results RECLTD REC Limited Board Meeting BPCL Bharat Petroleum Corporation Limited Board Meeting IOC Indian Oil Corporation Limited Board Meeting NMDC NMDC Limited Board Meeting

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SUNPHARMA files new disclosures

Track SUNPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.